Trial Profile
A postmarket surveillance registry of the BioMatrix drug eluting stent in diabetic patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Sponsors Biosensors International Group
- 23 Jun 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India record.
- 28 Nov 2011 New trial record